Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peptic Ulcers - Overview
Peptic Ulcers - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peptic Ulcers - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peptic Ulcers - Companies Involved in Therapeutics Development
Addpharma Inc
Axsome Therapeutics Inc
CalyGene Biotechnology Inc
Cinclus Pharma AG
Daewoong Pharmaceutical Co Ltd
Edenbridge Pharmaceuticals LLC
FortuneRock (Chi) Ltd
Hun Mingrui Pharmaceutical Co Ltd
Hun Sailong Pharmaceutical Co Ltd
Ilyang Pharmaceutical Co Ltd
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Korea Pharma Co Ltd
Kukje Pharmaceutical Industry Co Ltd
PharmaKing Co Ltd
PharmGen Science Inc
RaQualia Pharma Inc
Sotex Pharm Firm
XuanZhu Biological Technology Co Ltd
Peptic Ulcers - Drug Profiles
(meloxicam + esomeprazole) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
famotidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexuprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrrolate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilaprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-2150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IYIC-062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-3571 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
konolazan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
liprazan glurate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMKS-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabeprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9X0123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vonoprazan acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WRDN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptic Ulcers - Dormant Projects
Peptic Ulcers - Discontinued Products
Peptic Ulcers - Product Development Milestones
Featured News & Press Releases
Oct 22, 2021: Sihuan Pharmaceutical Holdings Group: New Drug Application of Xuanzhu Biopharm’s drug Aprazole Sodium accepted by NMPA
Mar 12, 2020: Gastroesophageal reflux disease new drug K-cap, Helicobacter pylori eradication indication
Feb 13, 2020: Sihuan Pharmaceutical Holdings Group: Commencement of phase III clinical trial in the PRC for self-developed innovative patented drug Aprazole Sodium
Apr 25, 2019: Sihuan Pharm’s innovative digestive system drug Aprazole Sodium achieved early completion of patient recruitment for phase II clinical trial in Chi
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Aprazole Sodium Category 1.1 New Drug Clinical Studies
Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Peptic Ulcers, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Peptic Ulcers, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Peptic Ulcers - Pipeline by Addpharma Inc, 2021
Peptic Ulcers - Pipeline by Axsome Therapeutics Inc, 2021
Peptic Ulcers - Pipeline by CalyGene Biotechnology Inc, 2021
Peptic Ulcers - Pipeline by Cinclus Pharma AG, 2021
Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Edenbridge Pharmaceuticals LLC, 2021
Peptic Ulcers - Pipeline by FortuneRock (China) Ltd, 2021
Peptic Ulcers - Pipeline by Hunan Mingrui Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Hunan Sailong Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Ilyang Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021
Peptic Ulcers - Pipeline by Korea Pharma Co Ltd, 2021
Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2021
Peptic Ulcers - Pipeline by PharmaKing Co Ltd, 2021
Peptic Ulcers - Pipeline by PharmGen Science Inc, 2021
Peptic Ulcers - Pipeline by RaQualia Pharma Inc, 2021
Peptic Ulcers - Pipeline by Sotex Pharm Firm, 2021
Peptic Ulcers - Pipeline by XuanZhu Biological Technology Co Ltd, 2021
Peptic Ulcers - Dormant Projects, 2021
Peptic Ulcers - Dormant Projects, 2021 (Contd..1)
Peptic Ulcers - Discontinued Products, 2021